IASIS PHARMA has launched a new pharmaceutical product under the brand name of ZALEPIN® RAPID, enriching its CNS product portfolio.
ZALEPIN® RAPID contains Olanzapine as its active ingredient and belongs to the class of atypical antipsychotic agents, the newer generation of antipsychotics.

ZALEPIN® RAPID is available in the form of orodispersible tablets (ODT), offering the benefits of:
• immediate drug therapy intervention,
• convenient for administration and patient compliant for disabled, bedridden patients and people who do not always have access to water, or have difficulty to swallow,
• good mouth feel property helps to change the perception of medication particularly in psychiatric patients
• improved patient compliance.

ZALEPIN® RAPID is marketed in 3 strengths: 5mg/ or.dis. tab, 10mg/ or.dis. tab & 20mg/ or.dis. tab, in packs of 28 orodispersible tablets.